Physician profile
Eric D Blacher
NPI 1477789667
$9,187.06
in general payments reported to CMS, 2019-2025
32 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $809 · 2021: $958 · 2022: $1,068 · 2023: $1,180 · 2024: $1,978 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,197.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,193.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,136.20 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $912.76 | 2019-2025 | Rinvoq |
| Gilead Sciences, INC. | $863.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $631.40 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.67 | 2019-2025 | Jardiance, Spiriva Respimat, Tradjenta |
| Merck Sharp & Dohme LLC | $424.53 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amgen INC. | $308.90 | 2020-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $295.29 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $276.19 | 2024-2025 | Gemtesa |
| Horizon Therapeutics Plc | $249.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $150.44 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $133.28 | 2022-2025 | |
| Exact Sciences Corporation | $125.36 | 2023-2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $117.55 | 2019-2023 | Eliquis |
| Lilly USA, LLC | $111.78 | 2019-2025 | Jardiance |
| Currax Pharmaceuticals LLC | $76.96 | 2021-2023 | Contrave |
| Shield Therapeutics INC | $51.03 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $43.58 | 2024 | Injectafer |
| Amarin Pharma, INC. | $34.11 | 2019-2022 | |
| Viiv Healthcare Company | $33.54 | 2023-2024 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.96 | 2023 | Quviviq |
| Astellas Pharma US INC | $21.21 | 2019 | |
| Boston Scientific Corporation | $19.69 | 2024 | Resonate El Icd Vr |
| Dynavax Technologies Corporation | $19.43 | 2023 | Heplisav-B |
| Lundbeck LLC | $18.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.36 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.08 | 2019 | |
| Seqirus USA INC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Blacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.